Patients with malignant pleural mesothelioma (MPM) lived 6 months longer, on average, when they had surgery in addition to chemotherapy, a large retrospective analysis showed.
The addition of surgery to combination chemotherapy resulted in a median overall survival (OS) of 22 months as compared with 16 months with chemotherapy alone. Twice as many patients remained alive at 5 years with surgery, and four times as many lived 10 years or longer if they underwent surgery, although long-term survival remained poor, with or without surgery, reported Ahmed Alnajar, MD, of the University of Miami, at the virtual World Conference on Lung Cancer (WCLC).
“Our study demonstrated how poor survival rates were associated with MPM, as an overall survival outcome,” said Alnajar. “However, surgical treatment has played a role in improving survival, and academic programs improved survival, based on their overall management plans.”
The findings added some positive data to a persisting controversy over surgery’s role in the management of MPM. A decade ago, the Mesothelioma and Radical Surgery (MARS) study showed not only that radical surgery did not improve outcomes in MPM but conferred a high morbidity that precluded future large randomized trials. However, other feasibility trials and prospective studies showed more positive outcomes with surgery, including median OS exceeding 2 years, said Alnajar.
The study is the latest, and one of the largest, to examine the role of surgery for MPM, said WCLC invited discussant Francoise Galateau-Sallé, MD, of Leon Berard Cancer Center in Lyon, France. The size of the patient population, use of propensity matching, and identification of risk factors that influence survival after surgery are the principal strengths and clearly showed a benefit of surgery.
But those have to be balanced against the possible confounding effects of selection bias, lack of details about histologic features, and lack of information about characteristics of long survival that distinguish responders and nonresponders, Galateau-Sallé noted.
Recent reviews have come down on both sides of the issue, Galateau-Sallé said. Authors of a review published in 2020 found a lack of supporting evidence for surgery from randomized trials. Literature that supports surgical resection “is biased by patient selection for the earliest stage, healthiest patients.”[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation
Free. Confidential. No Obligation.